Children With HIV and Asthma (CHIVAS)

Allergen Specific T Effector and T Regulatory Cell Response to Common Aeroallergens Following Immune Restoration in HIV-infected Children

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01644370

Enrollment

Registered

2012-07-19

Start date

2011-09-30

Completion date

2015-12-31

Last updated

2016-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T Cell Response to Asthma in HIV-infected Patients Before and After Starting Treatment

Keywords

HIV-infected children, T cell response, asthma

Brief summary

To explore allergen-specific effector and regulatory T cell response in HIV-infected children before and after HAART initiation

Detailed description

Recently, US investigators have observed that HIV-infected (HIV+) children on highly active antiretroviral therapy (HAART) have a much greater cumulative incidence of asthma.Regulatory T cells may mitigate the pathogenicity of asthma through the suppression of Th2 responses. Since asthma is predominantly a TH2 mediated condition, we propose that new onset of asthma after HAART in HIV- infected children may be secondary to dysregulated immune reconstitution. The restoration of CD4+ T cell-mediated immunity in HIV+ patients treated with HAART may lead to airway inflammation, narrowing, hyperresponsiveness, and possibly remodeling. The increased incidence of asthma in HIV-infected children treated with HAART is likely secondary to multiple factors that may include hypersensitivity to certain aeroallergens, dysregulation of effector and regulatory T cell response, as well as the imbalance of TH1 vs. TH2 cytokines. Therefore this study will identify the immunopathogenesis of increased airway hyperresponsiveness in HIV-positive patients.

Interventions

DRUGHAART

as per Thai HIV Treatment guidelines

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

1. Children aged 2-18 years 2. Parent signed inform consent and children signed assent form 3. Children who are starting highly active antiretroviral therapy (HAART) due to clinical indication or switching HAART due to treatment failure within 45 days after screening visit

Exclusion criteria

1. Pregnancy 2. History of chronic lung disease including lymphoid interstitial pneumonitis (LIP), and bronchopulmonary dysplasia (BPD). 3. Active opportunistic infections i.e. pulmonary tuberculosis, PCP, pneumonia 4. Conditions limiting ability of subject to comprehend questionnaires (i.e. mental retardation).

Design outcomes

Primary

Measure	Time frame	Description
T cell response	24 weeks	exploring T cell response by immunophenotyping and cytokine detection in HIV-infected children before and after HAART initiation

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026